marked.bio

Company

Stemline Therapeutics

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

elacestrant 3alpelisib 1everolimus 1ribociclib 1palbociclib 1capivasertib 1abemaciclib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

3 of 3 trials shown

  1. A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

    Recruiting Phase 2 Stemline Therapeutics Started 2026Primary completion 2028-10 NCT07766018

    elacestrant FDA EU

    Participants must be ESR1-mutant positive determined via testing with the Guardant360 Companion Diagnostic panel test prio…

    ESR1 mutationBreast Cancer

  2. Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

    Active, not recruiting Phase 1/2 Stemline Therapeutics Started 2023Primary completion 2026-12 NCT05563220

    elacestrantalpelisib FDA EUeverolimusribociclibpalbociclib FDA EUcapivasertib FDA EUabemaciclib

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation by local laboratory assessment.

    PIK3CA activating mutationBreast Cancer, Metastatic Breast Cancer

  3. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    Recruiting Phase 1 Stemline Therapeutics Started 2024Primary completion 2027-10 NCT06638307

    MEN2312elacestrant

    Presence of genetic alterations in PIK3CA/AKT1/PTEN in participants' tumor tissue.

    PIK3CA activating mutationAdvanced Breast Cancer